gland pharma glp-1 capacity expansion reported a strong December quarter with 22.5% revenue growth and 27% YoY profit growth, driven by healthy performance across the US, India, and Europe. The stock reacted positively, gaining over Visibility - All Denied a GLP-1? It's packes:5

gland pharma glp-1 capacity expansion reported a strong December quarter with 22.5% revenue growth and 27% YoY profit growth, driven by healthy performance across the US, India, and Europe. The stock reacted positively, gaining over Visibility - All Denied a GLP-1? It's packes:5

Denied a GLP-1? It's usually the paperwork — not you. Most denials come down to documentation: prior attempts nobody wrote down, a BMI that never made it into the chart, a deadline

Fitness tools through the Muscle Defense™ program and a community of “Noomers” round it out

Visibility - All

packes:5

Head-to-head — SURMOUNT-5 (NEJM May 2025)